# A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

> **NCT05372419** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 90 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Lebrikizumab

## Key facts

- **NCT ID:** NCT05372419
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2024-05-03
- **Final completion:** 2025-02-17
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372419, "A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05372419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*